128 related articles for article (PubMed ID: 37056386)
1. Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer.
Wu Y; Yin H; Zhang X; Shen R; Zhu X; Jia M
J Cancer; 2023; 14(5):784-792. PubMed ID: 37056386
[TBL] [Abstract][Full Text] [Related]
2. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer.
Bai S; Chen T; Du T; Chen X; Lai Y; Ma X; Wu W; Lin C; Liu L; Huang H
Oncol Lett; 2017 Dec; 14(6):6801-6808. PubMed ID: 29163701
[TBL] [Abstract][Full Text] [Related]
3. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway.
Liu X; Li T; Huang X; Wu W; Li J; Wei L; Qian Y; Xu H; Wang Q; Wang L
Oncol Lett; 2020 Nov; 20(5):146. PubMed ID: 32934714
[TBL] [Abstract][Full Text] [Related]
4. A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK.
Su YF; Liang CY; Huang CY; Peng CY; Chen CC; Lin MC; Lin RK; Lin WW; Chou MY; Liao PH; Yang JJ
J Biomed Sci; 2014 Aug; 21(1):67. PubMed ID: 25091805
[TBL] [Abstract][Full Text] [Related]
5. Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.
Matte I; Garde-Granger P; Bessette P; Piché A
Am J Cancer Res; 2019; 9(1):160-170. PubMed ID: 30755819
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
7. High Expression of DEPDC1B Predicts Poor Prognosis in Lung Adenocarcinoma.
Li P; Chen X; Zhou S; Xia X; Wang E; Han R; Zeng D; Fei G; Wang R
J Inflamm Res; 2022; 15():4171-4184. PubMed ID: 35912402
[TBL] [Abstract][Full Text] [Related]
8. Aberrantly high DEPDC1B expression leads to poor prognosis in patients with lower-grade gliomas.
Liu ZD; Liang WJ; Cheng XB; Qian RJ; Gao YZ
Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):7813-7826. PubMed ID: 36394729
[TBL] [Abstract][Full Text] [Related]
9. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
10. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
Yang HM; Lou G
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
[No Abstract] [Full Text] [Related]
11. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
Ma Z; Wang X; He J; Xia J; Li Y
PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
[TBL] [Abstract][Full Text] [Related]
12. DEP Domain-Containing Protein 1B (DEPDC1B) Promotes Migration and Invasion in Pancreatic Cancer Through the Rac1/PAK1-LIMK1-Cofilin1 Signaling Pathway.
Zhang S; Shi W; Hu W; Ma D; Yan D; Yu K; Zhang G; Cao Y; Wu J; Jiang C; Wang Z
Onco Targets Ther; 2020; 13():1481-1496. PubMed ID: 32110046
[TBL] [Abstract][Full Text] [Related]
13. DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis.
Xu Y; Sun W; Zheng B; Liu X; Luo Z; Kong Y; Xu M; Chen Y
Exp Cell Res; 2019 Jun; 379(1):48-54. PubMed ID: 30880030
[TBL] [Abstract][Full Text] [Related]
14. Promoter Methylation of the
Li XF; Sun HY; Hua T; Zhang HB; Tian YJ; Li Y; Kang S
Front Oncol; 2021; 11():659254. PubMed ID: 34268111
[TBL] [Abstract][Full Text] [Related]
15. DEPDC1B is a key regulator of myoblast proliferation in mouse and man.
Figeac N; Pruller J; Hofer I; Fortier M; Ortuste Quiroga HP; Banerji CRS; Zammit PS
Cell Prolif; 2020 Jan; 53(1):e12717. PubMed ID: 31825138
[TBL] [Abstract][Full Text] [Related]
16. Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B) monoclonal antibodies.
Igase M; Morinaga Y; Kato M; Tsukui T; Sakai Y; Okuda M; Mizuno T
J Vet Med Sci; 2020 Apr; 82(4):483-487. PubMed ID: 32147621
[TBL] [Abstract][Full Text] [Related]
17. Identification of the GTPase-activating protein DEP domain containing 1B (DEPDC1B) as a transcriptional target of Pitx2.
Wu D; Zhu X; Jimenez-Cowell K; Mold AJ; Sollecito CC; Lombana N; Jiao M; Wei Q
Exp Cell Res; 2015 Apr; 333(1):80-92. PubMed ID: 25704760
[TBL] [Abstract][Full Text] [Related]
18. The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling.
Li Z; Wang Q; Peng S; Yao K; Chen J; Tao Y; Gao Z; Wang F; Li H; Cai W; Lai Y; Li K; Chen X; Huang H
Clin Transl Med; 2020 Oct; 10(6):e191. PubMed ID: 33135357
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of DEPDC1B inhibits the development of glioblastoma.
Chen X; Guo ZQ; Cao D; Chen Y; Chen J
Cancer Cell Int; 2020; 20():310. PubMed ID: 32684847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
